Public Beta

We are thrilled to announce that Psilmi™, our patent-pending platform for AI-driven digital biomarkers in psychiatry, is now available in beta!
Psilmi uses structured visual stimuli and high-precision eye tracking to capture objective physiological signals, transforming them into interpretable biomarker features. Our goal: move beyond subjective questionnaires toward biology-linked measures for conditions such as autism, ADHD, depression, and anxiety.

Join the Beta Program

Test Psilmi in real-world research settings
Run pilot studies with your clinic or research site
Contribute feedback and shape the future of digital psychiatry

Learn more and download the beta: Stardots Psilmi™

What’s next?

Expanding pilot studies with clinics and psychiatrists worldwide
Preparing for confirmatory clinical trials and FDA 510(k) submission

Together, we’re building a new standard for mental health assessment.